Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK "This ...
Irish Independent on MSN1d
Wicklow mother calls for access to life-saving therapy for son with rare form of Cystic FibrosisA Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...
The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...
Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...
A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...
helping reduce the symptoms of cystic fibrosis. However, these medications are only effective in people with specific CFTR mutations. Therefore, doctors will choose the type of CTFR modulator ...
As Healio previously reported, the FDA recently approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations based, in part, on data from these trials ...
Advances in genetic testing, enable the identification of genetic causes even before symptoms appear, allowing for timely ...
Medical Xpress on MSN11d
New animal model offers insights into pancreatic disease and diabetesCystic fibrosis (CF) is a life-threatening genetic disease ... related diabetes (CFRD), a condition affecting up to 50% of ...
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback